-
CDE publicly solicits opinions on 2 technical guidelines
Time of Update: 2021-10-21
On October 11, the CDE official website publicly solicited opinions on two technical guidelines, namely, the technical guidelines for the clinical research and development of rare disease drugs and the technical guidelines for the design of long-acting granulocyte colony stimulating factors to prevent infection after chemotherapy (draft for comments) .
-
With the accelerated innovation of pharmaceutical companies, the AI drug research and development track is getting hotter and hotter
Time of Update: 2021-10-21
For a long time, new drugs have been characterized by difficult design, high cost, and time-consuming. On average, the industry’s previous research and development of a new drug required "10 years an
-
Domestically-made innovative drugs are going overseas, and new progress is being made
Time of Update: 2021-10-21
On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company’s self-developed innovative drug "TCR1672" has been submitted to the U.
Andorra's new anti-cancer drug AND019 has been approved for clinical use in the United States Hangzhou Andorra's third-generation oral breast cancer class 1 new drug AND019, independently developed by Hangzhou Andorra Co.
-
Yin Honggang, Director, Deputy General Manager, Board Secretary and Chief Financial Officer of Kangyuan Pharmaceutical, resigns
Time of Update: 2021-10-21
Yin Honggang, director, deputy general manager, secretary of the board and chief financial officer.
Yin Honggang will not affect the normal operation of the company's daily operations, and the resignation report will take effect on the day it is delivered to the board of directors .
-
Under the implementation of the new regulations, the ophthalmic consumables market will usher in a major reshuffle!
Time of Update: 2021-10-21
At the same time, policies are also leaning toward the industry, adding assistance to the development of the domestic ophthalmic medical device industry, and the market scale is expected to continue to expand .
-
Fuhong Hanlius LAG-3 monoclonal antibody completed the first subject administration
Time of Update: 2021-10-21
On October 12, Henlius announced that its self-developed recombinant humanized anti-LAG-3 humanized monoclonal antibody injection HLX26 for the treatment of solid tumors and lymphoma in the phase 1 clinical study is in China (excluding Hong Kong, Macao and Taiwan).
-
A pharmaceutical company was raided by tax and a multinational pharmaceutical company laid off employees in India
Time of Update: 2021-10-21
According to Indian media reports, last week, the Indian tax authority raided the Hyderabad-based Hetero pharmaceutical company and found unidentified income of up to 5.
Both drugs were approved in India last year for the treatment of new coronavirus infections, so Cidron Pharmaceuticals It has also become the focus of attention.
-
Digitization empowers the Chinese medicine industry and accelerates its entry into the "fast lane of development"
Time of Update: 2021-10-21
In recent years, with the increasing demand for health and the emergence and development of new technologies such as the Internet, big data, and artificial intelligence, China's traditional Chinese medicine market has also begun to be injected with new vitality .
-
Chinese medicine is facing many challenges under the acceleration of "going to sea"
Time of Update: 2021-10-21
Among them, the main problem affecting the development of Chinese medicine overseas markets is that Chinese medicine has so far lacked a unified scientific standard that can be recognized by Western countries .
-
Hunan accelerates the export of Hunan medicine to promote the internationalization of Chinese herbal medicine industry
Time of Update: 2021-10-21
Chen Fei, vice governor of the Hunan Provincial People’s Government, said that he hopes that all parties to the contract will use this signing as an opportunity to deepen communication, strengthen strategic coordination, and give full play to the scientific and technological platforms of Hunan, Guangdong and Macao such as the academician Liu Liang’s expert workstation and the Qingfengteng Research Institute.
-
Has invested 350 million yuan in Hengrui's topical JAK1 inhibitor phase II clinical success
Time of Update: 2021-10-21
On October 11, Hengrui Medicine announced that the double-blind, excipient-controlled, phase II/III phase II/III seamless adaptive design clinical study RSJ10431 (MARBLE23) of SHR0302 alkali ointment for the treatment of atopic dermatitis developed by its subsidiary Ruishi Biotechnology Among them, the 0.
-
"Unmanned pharmacies" pilot projects in many places across the country to solve the problem of finding drugs late at night
Time of Update: 2021-10-21
It is reported that on June 28, Yantai's first smart medicine storage cabinet that can sell prescription drugs and over-the-counter drugs has been approved and put into use .
-
Tasly Compound Danshen Dripping Pills Obtained the Notice of Approval of Drug Supplementary Application
Time of Update: 2021-10-21
In 2008, the company submitted a clinical supplementary application (acceptance number: CYZB0803905) for the compound Danshen dripping pill to increase the indications of diabetic retinopathy to the Drug Evaluation Center of the State Food and Drug Administration.
-
6 pharmaceutical enterprise projects are selected into the Ministry of Industry and Information Technology's 2021 new generation information technology and manufacturing integrated development pilot demonstration list
Time of Update: 2021-10-21
: Production Quality Traceability Capability of Traditional Chinese Medicine Formula Granules New Green Pharmaceutical is a company mainly engaged in the research and development, production and operation of traditional Chinese medicine prescription granules, covering Chinese herbal medicine decoction pieces, new Chinese herbal medicines, and the major health industry of Chinese medicine.
-
Beishangguang sells TOP10!
Time of Update: 2021-10-21
Anti-tumor drugs are still the main drug in the three cities of Beijing, Shanghai and Guangzhou; Lipitor has grown against the trend, lung cancer star drugs have declined for the first time, and the sales of the three major brands have doubled; Zhu, CSPC, Qilu, Yangtze River.
-
Saisheng Pharmaceutical declares for listing of new antibiotic Tilavacin Hydrochloride for injection
Time of Update: 2021-10-21
According to the prospectus of Saisheng Pharmaceutical, the market size of anti-MRSA antibacterial drugs in China in 2019 is RMB 4.
-
Benxi, Liaoning, develops traditional Chinese medicinal materials industry in accordance with local conditions
Time of Update: 2021-10-21
Benxi High-tech Zone will create a new landmark in the biomedicine industry and build an ecological city through the development of medical and health industries including modern Chinese medicine .
-
The AI pharmaceutical track is hot, and another leading pharmaceutical company successfully IPO
Time of Update: 2021-10-21
Early shareholders such as Sequoia Capital and Wuyuan Capital continued to make additional investments; in early August, Shenzhen Technology announced that it had completed a series of tens of millions of dollars in A round of financing led by Hillhouse Ventures and co-invested by Matrix Partners China and Baitu Shengke .
-
The tens of billions of diabetes drug market has become a new focus of local drug companies
Time of Update: 2021-10-21
Recently, Huadong Medicine announced that it signed an exclusive product commercialization agreement with multinational pharmaceutical company Takeda (Takeda Pharmaceutical), and obtained the exclusive commercialization of Takeda Pharmaceutical’s innovative product Alogliptin benzoate tablets (trade name: Nisina) in mainland China Equity .
-
Guangdong ushered in 61 kinds of centralized procurement drugs, an average decrease of 55%
Time of Update: 2021-10-21
In addition to the aforementioned Guangdong Province’s price linkage for non-selected drugs of the same generic name, Henan Province also recently issued a notice on the evaluation results of the fifth batch of national centralized procurement of non-selected drugs.
